Massive cancer databank aims to personalize treatment

NCT ID NCT05061342

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is creating a large databank of blood, imaging, and tissue samples from 5,000 cancer patients. Researchers will track how patients respond to various treatments—including surgery, radiation, and chemotherapy—and look for biomarkers that predict tumor control, side effects, and quality of life. The goal is to better understand which treatments work best for which patients, but this is an observational study, not a test of a new therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this databank could help doctors predict which cancer treatments work best for each patient, improving personalized care.

What could go wrong

This is an observational study, not a treatment trial. It collects data but does not test any new drug or therapy, so it won't directly change patient care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UHongKongShenzhen

    RECRUITING

    Shenzhen, Guangdong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••